Young people’s risk of developing myocarditis is higher and longer lasting after covid-19 infection than after vaccination against it, the largest study of its kind suggests.1 The research—based on ...

The largest study of its kind has revealed that the Pfizer-BioNTech Covid-19 vaccine presents considerably fewer problems for ...

A new study shows children and young people face long-lasting and higher risks of rare heart and inflammatory complications ...

Rare vascular and inflammatory conditions such as blood clots, myocarditis, and pericarditis occur more often in children ...

Children and adolescents had higher risks of vascular and inflammatory diseases after a first COVID diagnosis, as well as a ...

Children face longer-lasting and higher risks of rare heart and inflammatory conditions after a COVID-19 infection than after ...

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following ...

The latest announcement is out from Cardiol Therapeutics ( (TSE:CRDL) ).

The risk of rare heart, vascular, or inflammatory complications in children is higher after Covid-19 infection than after Covid vaccination.

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, ...

Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.